Table 2. Case series of patients with VN.
MVS: maximum velocity of the slow phase of caloric nystagmus; CP: canal paresis; cVEMP: cervical vestibular evoked myogenic potential; oVEMP: ocular VEMP; MRI: magnetic resonance imaging; CT: computed tomography; HT: hypertension; HL: hyperlipidemia; CI: chronic ischemia; LV: poor arterial tracing of the left vertebra; LMS: left maxillary sinusitis; NSW: nonspecific white matter lesion
| # | Age (years) | Sex | Onset after 1st dose (days) | Onset after 2nd dose (days) | Number of days between onset and testing | Laterality | Caloric MVS (degree/s) | CP% | cVEMP 500Hz p13-n23 (µV) | cVEMP 1kHz p13-n23 (µV) | oVEMP 500Hz n1-p1 (µV) | oVEMP 1kHz n1-p1 (µV) | Comorbidities | MRI | CT | |||||
| Right | Left | Right | Left | Right | Left | Right | Left | Right | Left | |||||||||||
| 1 | 85 | F | 65 | 44 | 30 | R | 0 | 14.5 | 100% | 0 | 0 | 0 | 0 | 0 | 2.238 | 0 | 0 | HT, nephrotic syndrome | CI | CI |
| 2 | 79 | F | 81 | 52 | 19 | R | 0 | 50.5 | 100% | 0 | 152.2 | 0 | 182.6 | 0 | 0 | 0 | 0 | HT, HL, HC, hyperuricemia | CI, LV | CI |
| 3 | 39 | M | 114 | 93 | 25 | R | 5.1 | 32.5 | 73% | 238.5 | 305.5 | 286.3 | 235.3 | 0 | 1.393 | 3.133 | 0 | No comorbidities | Not tested | Not tested |
| 4 | 71 | F | 69 | 48 | 88 | R | 9.5 | 25.5 | 46% | 0 | 0 | 0 | 0 | 0 | 4.32 | 7.253 | 0 | HT, HL | Chronic ischemia | Not tested |
| 5 | 50 | M | 46 | 18 | 17 | L | 30 | 0 | 100% | 0 | 0 | 121.6 | 100.9 | 1.2 | 2.2 | 1.5 | 0 | No comorbidities | No problem | No problem |
| 6 | 69 | M | 80 | 59 | 35 | L | 50 | 5 | 82% | 0 | 0 | 49 | 0 | 0.88 | 0.9 | 0 | 0 | HT, HL | CI | CI |
| 7 | 59 | F | 139 | 97 | 97 | R | 3 | 18 | 71% | 0 | 0 | 0 | 81.4 | 0 | 0 | 0 | 0 | HT | LMS, NSW | No problem |